Building on the success of 2017, the 2018 Clinical Biomarkers & World CDx Boston iteration will continue to cement the biomarker and translational development content at the heart of the meeting, enabling attendees to take a journey along the whole development continuum from exploratory biomarker, through clinical validation, past regulatory and reimbursement hurdles and into a globally adopted drug-Dx product.
For 2018 we have two overarching themes that underpin and flow through the whole meeting:
The four day meeting is split into two halves: pre-conference and main conference. Our pre-conference days will contain half-day workshop sessions, designed to take deep, interactive dives into a specific subject area. The main two day conference is separated into three streams covering translational development, clinical validation and implementation and drug-Dx commercialisation.
Click below to find out more about our biomarker and diagnostic sides to the event.